Log In
Print
BCIQ
Print
Print this Print this
 

Omeclamox-Pak

  Manage Alerts
Collapse Summary General Information
Company Pernix Therapeutics Holdings Inc.
DescriptionTen-day therapy of 20 mg omeprazole delayed-release capsules, 500 mg clarithromycin tablets and 500 mg amoxicillin capsules
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationHelicobacter
Indication DetailsTreat Helicobacter pylori infection and duodenal ulcer disease
Regulatory Designation
Partner Cumberland Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today